A Case Report for Acute Myopericarditis After NVX-CoV2373 (Novavax®) COVID-19 Vaccination

J Korean Med Sci. 2022 Aug 29;37(34):e265. doi: 10.3346/jkms.2022.37.e265.

Abstract

Post-vaccination myocarditis after administration of the NVX-CoV2373 coronavirus disease 2019 (COVID-19) vaccine has been reported in a limited population. We report the first biopsy-proven case of myopericarditis after administration of second dose of NVX-CoV2373 COVID-19 vaccine (Novavax®) in Korea. A 30-year-old man was referred to emergency department with complaints of chest pain and mild febrile sense for two days. He received the second dose vaccine 17 days ago. Acute myopericarditis by the vaccination was diagnosed by cardiac endomyocardial biopsy. He was treated with corticosteroid 1 mg/kg/day for 5 days and tapered for one week. He successfully recovered and was discharged on the 12th day of hospitalization. The present case suggests acute myopericarditis as a vaccination complication by Novavax® in Korea.

Keywords: Acute Myocarditis; COVID-19 Vaccine; Novavax.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • COVID-19 Vaccines* / adverse effects
  • COVID-19* / prevention & control
  • Humans
  • Male
  • Myocarditis* / complications
  • Myocarditis* / etiology
  • Pericarditis* / diagnosis
  • Pericarditis* / etiology
  • Vaccination / adverse effects

Substances

  • COVID-19 Vaccines
  • NVX-CoV2373 adjuvated lipid nanoparticle